Neovasculogenesis stimulation is a new trend in the treatment of chronic arterial occlusive diseases of lower extremities


Cite item

Full Text

Abstract

An analysis of experimental investigation of 70 male Vistar rates and results of examination and treatment of 30 patients suffered by chronic low limbs ischemia caused by atherosclerosis has been completed. All experimental animals
were divided into three groups: healthy, control, and investigated respectively. A chronic limb ischemia was achieved
by excision of the main vessel such as femoral, popliteal, and upper part of calf vessels. Having achieved an ischemia
a treatment was not done in the control group. Whereas animals of the control group received injection of platelet enriched autoplasm into the calf and thigh muscles. It was discovered that intramascular injection of platelet enriched
autoplasm into the animal’s ischemic limb increases microcirculation level 2,4 times and dicreases area of muscular
necrosis by 2,4 times to 28 experimental day. In patients 500 ml of blood were derived, from which a platelet enriched
plasma was made. 100 ml of the plasma were injected under ultrasound guidance along the deep femoral and popliteal arteries of the more 2nd “b” degree ischemic limb. A contralateral limb was used as a control group. After the treatment a blood flow volume was increased 1,4 times, main 885,08– in 1,3 times, and microcirculation level – in 1,2 times.

About the authors

Boris Semenovich Sukovatykh

Kursk state medical University

Author for correspondence.
Email: kaf.obsh_hir@kurskmed.com

 MD, Professor,  head of the Department of General surgery

Russian Federation, Kursk, Karla Marksa street, 3

Anzhelika Yur'evna Orlova

Kursk state medical University

Email: kaf.obsh_hir@kurskmed.com

 post-graduate student ka-Phaedra General surgery

Russian Federation, Kursk, Karla Marksa street, 3

References

  1. Бокерия Л.А., Еремеева Н.В. Современное состояние и перспективы использования ангиогенеза в лечении ишемической болезни сердца. Грудная и сердечно-сосудистая хирургия 2000; 2: 57-61.
  2. Бузиашвили Ю.И. Ангиогенез, как антиишемический фактор. Кардиология 2000; 12: 82–86.
  3. Давыденко В.В., Мачс В.М. Стимулированный ангиогенез – новое направление в лечении при ишемических состояниях. Вестник хирургии им. И.И.Грекова 2000;4: 117–120.
  4. Савельев В.С., Кошкин В.М. Критическая ишемия нижних конечностей. М.: Медицина 1997; 160.
  5. Шевченко Ю.Л. Медико-биологические и физиологические основы клеточных технологий в сердечно-сосудистой хирургии. СПб.: Наука 2006; 287.
  6. Al-Khaldi A. Therapeutic angiogenesis using autologous bone morrow stromal cells: improved blood flow in chronic limb ischemia model. Ann. Thorac. Surg. 2003; 75; 1: 204-209.
  7. Asahara T. VEGF contributes to postnatal neovascularization
  8. by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999; 18: 3964-3972.
  9. Hansen–Smith F. M., Hudlicka O.,Egginton S. In vivo angiogenesis in adult rat skeletal muscle: early changes in capillary network architecture and ultrastructure. Cell Tissue Res. 1996; 286; 1: 123-136.
  10. Iba. O. Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circ. 2002; 106: 2019-2025.
  11. Rutherford R.B. Recommended standards for reports dealing with lower extremity ischemia: Revised version. J. Vasc. Surg. 1997; 26: 516-538.
  12. Sandberg T. Paracrine stimulation of capillary cell migration tissue involves epidermal growth factor and is mediated via urokinase plastminogen activator receptor. J. Clin. Endocrinol. Metab. 2001; 86; 4: 1724-1730.
  13. Sugano C. Intramuscular gene transfer of soluble tumor necrosis factor-α activates vascular endothelial growth factor receptor and accelerates angiogenesis in a rat model hindlimb ischemia. Circulation 2004; 109: 797-802.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) Sukovatykh B.S., Orlova A.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies